Head to head
Medpace vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: MEDP · TMO
MEDP
Medpace
604.25+0.22%
1-year price shape — +14% over the period
Quant Rating C · 55/100
vs
TMO
Thermo Fisher Scientific
662.06+0.83%
1-year price shape — +23% over the period
Quant Rating C · 64/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific has the highest Quant Rating (64); Thermo Fisher Scientific has done best over the past year (+23%); Thermo Fisher Scientific pays the highest dividend yield.
| MEDP | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 604.25 | 662.06 |
| Change today | +0.22% | +0.83% |
| 1-year return | +13.6% | +23.1% |
| Market cap | $16.87B | $244.79B |
| 52-week range | 373.00 – 677.90 | 434.50 – 694.33 |
| Valuation | ||
| P/E (TTM) | 35.50 | 35.63 |
| P/E percentile, own 5-yr range | 76th | 86th |
| P/B | 38.87 | 4.65 |
| Dividend yield | 0.00% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | 15.28 | 17.74 |
| Net profit (TTM) | $426.49M | $6.56B |
| Revenue (TTM) | $2.78B | $46.34B |
| Revenue growth (YoY) | +17.2% | +10.5% |
| Gross margin | 28.8% | 40.8% |
| Operating margin | 21.0% | 18.3% |
| Net margin | 17.7% | 15.0% |
| Free cash flow (TTM) | $706.69M | $7.32B |
| Ownership & sentiment | ||
| Institutional ownership | 89.6% | 93.1% |
| Insider activity (12mo) | 23 buy / 24 sell | 22 buy / 28 sell |
| Short interest (% of float) | 6.0% | 1.4% |
| Analyst consensus | 22% buy / 78% hold (9) | 88% buy / 12% hold (17) |
| Analyst price target | $630 (+4%) | $653 (-1%) |
| StockVane view | ||
| StockVane Quant Rating | C (55) | C (64) |
| Company | ||
| Employees | 6,200 | 125,000 |
| Founded | 1992 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.